Lv1
80 积分 2023-11-30 加入
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
4天前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
8天前
已完结
Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia
19天前
已完结
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
25天前
已完结
Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia
25天前
已完结
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
1个月前
已完结
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
1个月前
已完结
Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)
2个月前
已关闭
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma patients: A single‐center, retrospective, cohort study
2个月前
已完结
CAR T-cell therapy in autoimmune diseases
4个月前
已完结
皖公网安备34019202002308
